DREAM-HF-1

STUDY IDENTIFIER:

DREAM-HF-1

CONDITION:

Chronic Heart Failure

CONTACT INFO:

Jane Fox, RN   |   Jane.Fox@allina.com   |   612-863-6289

DESCRIPTION:

The primary objective of this study is to determine whether the investigational transendocardial delivery of allogeneic human bone marrow-derived MPCs (rexlemestrocel-L) is effective for chronic heart failure due to LV systolic dysfunction.

CRITERIA LIST/ QUALIFICATIONS:

  • The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at least 6 months.
  • The patient is on stable, optimally tolerated dosages of HF therapies including beta-blockers (approved for country-specific usage), angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone antagonists, without change in dose for at least 1 month before study intervention.
  • The patient is on a stable, outpatient, oral diuretic dosing regimen in which the patient remains clinically stable during screening.
  • NYHA class I & IV are excluded.
 

INVESTIGATORS:

Mosi Bennett, MD

SPONSORS:

Mesoblast LTD

STATUS:

Open/Enrolling